Novartis Vanrafia Data Show Clinically Meaningful Kidney Protection In IgA Nephropathy
Novartis reported final Phase III ALIGN results for Vanrafia in adults with IgA nephropathy. According to the company, over 2.5 years Vanrafia cut the rate of kidney function decline by about 34% vs placebo and sustained lower proteinuria. In 340 patients, the annualized eGFR slope was -2.7 vs -4.1, and proteinuria fell 38.3% at nine months. Safety was similar to placebo; Novartis plans traditional approval submissions for 2026.
Clinically meaningful Phase III efficacy plus prior accelerated approvals increases probability of traditional approval and supports re-rating of Vanrafia/Iga nephropathy franchise expectations.
Novartis reported final Phase III ALIGN results showing Vanrafia slowed IgA nephropathy kidney function decline vs placebo over 2.5 years.
Near-term upside bias as traders price in stronger efficacy and 2026 traditional-approval submission momentum; magnitude depends on prior expectations.
Background
Vanrafia (approved on accelerated pathways in the U.S. and China in 2025 for proteinuria reduction) is now supported by final Phase III ALIGN efficacy data in IgA nephropathy.
Why it matters
Final Phase III results with quantified kidney-function slowing and sustained proteinuria reduction increase the likelihood of successful traditional-approval efforts and can shift valuation assumptions for NVS’s renal pipeline.
Market relevance
A concrete Phase III efficacy print for Vanrafia is a direct catalyst for NVS, with quantified endpoints and a stated path to 2026 traditional approval.
Market effects
Strengthens the renal/IgA nephropathy drug-development read-through for other late-stage nephrology assets and may lift sentiment toward proteinuria/kidney-protection endpoints.
Primarily impacts US-listed large-cap pharma sentiment; European renal congress presentation may reinforce global investor confidence.
Global investors may reassess the competitive landscape in IgA nephropathy based on magnitude of eGFR slope and proteinuria effects.
Alternative perspectives
If investors already priced in earlier signals, the incremental benefit may be less than expected and could fade after the initial headline move.
Traditional-approval timing (2026) and payer/label scope details are not provided; safety beyond prior studies and subgroup durability (e.g., with SGLT2 background) could drive follow-through.
Key entities
- companyNovartis
Sponsor of the Phase III ALIGN study for Vanrafia in IgA nephropathy; plans traditional approval submissions in 2026.
- drugVanrafia
Oral therapy evaluated in ALIGN; showed ~34% slower kidney decline vs placebo and sustained proteinuria reduction.
- clinical_trialALIGN study
Phase III trial in biopsy-proven IgA nephropathy; 340 patients randomized to Vanrafia vs placebo over ~132 weeks.
